Rosiglitazone attenuates endothelin-1-induced vasoconstriction by upregulating endothelial expression of endothelin b receptor

Keyphrases

• Vasoconstriction 100%
• Endothelin-1 (ET-1) 100%
• Rosiglitazone 100%
• Endothelin B Receptor 100%
• Mouse Aorta 50%
• ETB Receptor 50%
• Peroxisome Proliferator-activated Receptor 37%
• Gene Promoter 25%
• Thiazolidinediones 25%
• Molecular Mechanism 12%
• Promoter Activity 12%
• Protein Level 12%
• MRNA Level 12%
• Western Blotting 12%
• Vasoprotective Effect 12%
• Aorta Artery 12%
• Endothelium 12%
• Insulin Resistance 12%
• Endothelial Dysfunction 12%
• Receptor Antagonist 12%
• In Vivo Applications 12%
• NO Synthase Inhibitors 12%
• Northern Blotting 12%
• Chromatin Immunoprecipitation (ChIP) 12%
• Real-time RT-PCR 12%
• Receptor Gene 12%
• Mesenteric Artery 12%
• Immunohistochemical Method 12%
• Direct Target 12%
• Luciferase Reporter Assay 12%
• Receptor Antagonism 12%
• Human Vascular Endothelial Cells 12%
• Wire Myography 12%

Neuroscience

• Receptor 100%
• Rosiglitazone 100%
• Endothelin 100%
• Endothelin 1 100%
• Peroxisome Proliferator-Activated Receptor 37%
• Promoter Region 25%
• Thiazolidinedione 25%
• In Vivo 12%
• Receptor Gene 12%
• Receptor Antagonist 12%
• Western Blot 12%
• Messenger RNA 12%
• Nitric Oxide Synthase 12%
• Luciferase 12%
• Immunoprecipitation 12%
• Vasoprotective 12%
• Endothelin B Receptor 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Receptor 100%
• Endothelin 1 100%
• Rosiglitazone 100%
• Endothelin 100%
• Peroxisome Proliferator Activated Receptor 37%
• Thiazolidinedione 25%
• Messenger RNA 12%
• Western Blot 12%
• Nitric Oxide Synthase 12%
• Endothelial Dysfunction 12%
• Luciferase 12%
• Insulin Resistance 12%
• Chromatin Immunoprecipitation 12%
• Endothelin B Receptor Antagonist 12%